RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

In a conversation I had last year with a Big Pharma BusDev group about Cortex, they referred to the "fragmented" Ampakine rights with a tone of complete dismay. It's a complication they aren't used to seeing in an asset. So this does remove one obstacle 'down the road'--when, if the plan pans out (knocking on wood wherever available) they seek to partner CX-1739 for ADHD. It could expand into a broader psychiatric partnership that would not currently be possible.

NeuroInvestment